Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: Comparisons of cost and outcomes in Taiwan

Haemophilia

Volumn 17, Issue 1, 2011, Pages 45-54

  Liou, W S ^a,b   Tu, T C ^c,d   Cheng, S N ^d   Chou, T Y ^d   Lee, C F ^d   Lin, T K ^d   Chung, M I ^c   Cham, T M ^c  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cost; Factor concentrate; Haemophilia A; On demand; Pharmacoeconomics; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEMOPHILIA A; HUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TAIWAN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; HEALTH CARE COSTS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; RETROSPECTIVE STUDIES; TAIWAN; YOUNG ADULT;

EID: 79951985004     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02367.x     Document Type: Article

References (47)

1. Barr R, Saleh M, Furlong W. Health status and health-related quality of life associated with hemophilia. Am J Hematol 2002; 71: 152-60.
2. Tagliaferri A, Di Perna C, Rivolta GF. Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus 2008; 6(Suppl 2): s17-20.
3. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
4. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
5. Aledort L, Haschmeyer R, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The orthopaedic outcome study group. J Intern Med 1994; 236: 391-9.
6. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
7. Bohn R, Avorn J, Glynn R, Choodnovskiy I, Haschemeyer R, Aledort L. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 932-7.
8. Miners A, Sabin C, Tolley K, Lee C. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Intern Med 2000; 247: 493-9.
9. Szucs T, Offner A, Kroner B, Giangrande P, Berntorp E, Schramm W. Resource utilisation in haemophiliacs treated in Europe: results from the European study on socioeconomic aspects of haemophilia care. The European socioeconomic study group. Haemophilia 1998; 4: 498-501.
10. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
11. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl 1): 1-4.
12. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
13. Pipe S, Valentino L. Optimizing outcomes for patients with severe haemophilia A. Haemophilia 2007; 13(Suppl. 4): 1-16.
14. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
15. Ljung R. Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment options. Haemophilia 2007; 13(Suppl. 2): 1-3.
16. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101/4: 674-81.
17. Srivastava A, Giangrande P, Poon MC, Chua M, McCraw A, Wiedel J. Guidelines for the management of hemophilia. Available at Accessed June 29, 2009.
18. StataCorp LP. Stata Computer Statistical Package, Version 10. College Station, Texas, USA: Stata Press, 2007.
19. Ministry of the Interior. Life Expectancy Statistics. Taiwan: China, 2009.
20. Dolan G, Hermans C, Klamroth R, Madhok R, Schutgens REG U S. Challenges and controversies in haemophilia care in adulthood. Haemophilia 2009; 15: 20-7.
21. Miners A, Sabin C, Tolley K, Lee C. The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. Haemophilia 1998; 4: 9.
22. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
23. Chiang C, Chen P, Shen M, Tsai W. Total knee arthroplasty for severe haemophilic arthropathy: long-term experience in Taiwan. Haemophilia 2008; 14: 828-34.
24. Bureau of National Health insurance T, ROC. Data Sets for Hemophilia Patients: 1997-2007. Taiwan: China, 2008.
25. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
26. Department of Health ROC. Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996. Available at Accessed June 29, 2009.
27. Richards M, Altisent C, Batorova A, Chambost H. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007; 13: 473-9.
28. Cohen A, White E, Bernstein C. Effects of secondary prophylaxis in hemophilia children with frequent hemarthrosis. Transfusion 1997; 37: 534-5.
29. Carlsson K, Höjgård S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 8: 555-66.
30. Carcao MD, Aledort LM. Prophylaxis in the haemophilia population-optimizing therapy. Haemophilia 2007; 13: 227-32.
31. Ono O, Suzuki Y, Yosikawa K et al. Assessment of haemophiia treatment practice pattern in Japan. Haemophilia 2009; 15: 1032-8.
32. Ramsay DM, Khoo KK. A five-year study of a haemophilia reference centre. J Clin Pathol 1975; 28: 696-700.
33. Aronstam A, Rainsford SG, Painter MJ. Patterns of bleeding in adolescents with severe haemophilia A. Br Med J 1979; 1: 469-70.
34. Aronstam A. Haemophiliac Bleeding, Early Management at Home. London: Bailliere Tindall, 1985.
35. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
36. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
37. Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia 2003; 9(Suppl 1): 38-42. discussion 3.
38. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
39. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
40. Lippert B, Berger K, Berntorp E et al. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagul Fibrinolysis 2005; 16: 477-85.
41. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-40.
42. Smith PS, Teutsch TS, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
43. Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-Utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 2002; 20: 759-74.
44. Soucie J, Symons J IV, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemopnilia. Haemophilia 2001; 7: 198-206.
45. Colvin BT, Astermark J, Fischer K et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
46. Walsh C, Valentino L. Facor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21. Early View: 1-8.
47. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med 1997; 241: 395-400.